Organon & Co. OGN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
36/100
Developing

Ranked against 19 peers in Drug Manufacturers - General

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; … Full OGN analysis →

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.78), demonstrating pricing resilience across cycles.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.94), suggesting sticky customer base.

Key risks

  • ROIC Below WACC or Peers ROIC at 36.8th percentile suggests inefficient capital deployment.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.19), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
50
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where OGN ranks in Drug Manufacturers - General

Organon & Co. ranks #16 of 20 scored companies in Drug Manufacturers - General by moat score — the top 80%. The widest moat in the group is Novo Nordisk A/S (NVO) at 74/100.

# Company Moat score Rating
12 Grifols, S.A. GRFS 50/100 Developing
13 Eli Lilly and Company LLY 45/100 Developing
14 AbbVie Inc. ABBV 43/100 Developing
15 Pfizer, Inc. PFE 43/100 Developing
16 Organon & Co. OGN 36/100 Developing
17 Scilex Holding Company SCLX 27/100 Developing
18 Scilex Holding Company SCLXW 26/100 Developing
19 Amarin Corporation plc AMRN 23/100 Weak
20 MIRA Pharmaceuticals, Inc. MIRA 15/100 Weak

See every Pharma / Mature Biotech company ranked by moat score →

How OGN scores on the Corporate Default defenses

Pricing Power

Score 50 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 31 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 52 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 26 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 31 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 21 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding OGN's moat

What is Organon & Co.'s moat score?

Organon & Co. (OGN) scores 36 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #16 of 20 scored companies in Drug Manufacturers - General, the top 80%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Customer Stickiness (52/100) and its weakest is Scale & Market Position (21/100).

How does Organon & Co. compare with other Drug Manufacturers - General companies?

Organon & Co. ranks #16 of 20 scored companies in Drug Manufacturers - General by moat score. The widest moat in Drug Manufacturers - General is Novo Nordisk A/S (NVO) at 74/100. The companies ranked closest are Pfizer, Inc. (PFE) at 43 just above it and Scilex Holding Company (SCLX) at 27 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.

Why is Organon & Co. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Organon & Co.?

The Corporate Default template measures 6 defenses, and OGN scores: Pricing Power (50), Cost Advantage (31), Customer Stickiness (52), Capital Efficiency (26), Resilience (31), Scale & Market Position (21). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000